Prostate cancer is the most common cancer in men and the second leading cause of cancer mortality. In men younger than 65 years of age, the prostate cancer mortality rate for African Americans is 3.1 times that of Caucasian Americans. In men 65 years of age and older, the prostate cancer mortality rate for African Americans is 2.3 times that of Caucasian Americans.
The Prostate Cancer Research Program prioritizes research that will develop effective therapies for advanced prostate cancer or distinguish between indolent and aggressive disease. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
PCaP is the North Carolina-Louisiana Prostate Cancer Project. It is a research study funded by the Department of Defense. (The full name of the grant is Racial Differences in Prostate Cancer: Influence of Health Care and Host and Tumor Biology.)
HCaP-NC is a follow-up study of approximately 335 AA and 335 CA prostate cancer patients from the North Carolina - Louisiana Prostate Cancer Project (PCaP) cohort were enrolled 2-3 years after diagnosis and followed for up to 6 years (average 3.8 years). Data collected from annual telephone interviews, medical records, and community-level data sources are analyzed in conjunction with baseline PCaP data (available through a data sharing agreement) to quantify differences in treatment and health related quality of life over time.